ReviewJournal of oncology practice2019
Atrial Fibrillation and Stroke Risk in Patients With Cancer: A Primer for Oncologists.
Review in Journal of oncology practice, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Cancer as a Hidden Catalyst: Rethinking Postoperative Atrial Fibrillation After Cardiac Surgery.Journal of clinical medicine · 2026Review
- Incidence of new-onset atrial fibrillation after thoracic radiotherapy in non-small cell lung cancer: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Development and validation of a risk assessment tool for ischemic stroke in cancer patients.Scientific reports · 2025Article
- CHAThe American journal of cardiology · 2025Article
- Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation and Cancer: A Target Trial Emulation from SEER-Medicare Database.Cardiovascular drugs and therapy · 2025Article
- The Association of Malignancy With Stroke and Bleeding in Atrial Fibrillation: A Population-Based Cohort Study.JACC. CardioOncology · 2025Article
- Development and Validation of Machine Learning Algorithms to Predict 1-Year Ischemic Stroke and Bleeding Events in Patients with Atrial Fibrillation and Cancer.Cardiovascular toxicology · 2024Article
- Benefit and risk of oral anticoagulant initiation strategies in patients with atrial fibrillation and cancer: a target trial emulation using the SEER-Medicare database.Journal of thrombosis and thrombolysis · 2024Article
- Malignancy-associated ischemic stroke: Implications for diagnostic and therapeutic workup.CNS neuroscience & therapeutics · 2024Review
- Caught Between a Rock and a Hard Place: Anticoagulation in Atrial Fibrillation Patients With Cancer.JACC. Advances · 2023Article
- Outcomes and Discriminatory Accuracy of the CHAJACC. Advances · 2023Article
- Treatment of acute ischemic stroke in patients with active malignancy: insight from a comprehensive stroke center.Therapeutic advances in neurological disorders · 2023Article
- Atrial fibrillation and cancer: prevalence and relative risk from a nationwide study.Research and practice in thrombosis and haemostasis · 2023Article
- Comparative Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin Among Adults With Cancer and Atrial Fibrillation.Circulation. Cardiovascular quality and outcomes · 2022Article
- Treatment Options in AF Patients with Cancer; Focus on Catheter Ablation.Journal of clinical medicine · 2022Review
- Practical recommendations to combine small-molecule inhibitors and direct oral anticoagulants in patients with nonsmall cell lung cancer.European respiratory review : an official journal of the European Respiratory Society · 2022Review
- Use of oral anticoagulants among individuals with cancer and atrial fibrillation in the United States, 2010-2016.Pharmacotherapy · 2022Article
- Atrial fibrillation in older adults with cancer.Journal of geriatric cardiology : JGC · 2022Article
Corrections and comments
- Commented on by
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer and atrial fibrillation (AF) are common conditions, but for patients affected with both, there is a lack of data about management of anticoagulation and cerebrovascular outcomes. In the first section of this review, we summarize the most relevant studies on stroke risk and management of AF in patients with active cancer, attempting to answer questions of whether to anticoagulate, whom to anticoagulate, and what agents to use. In the second section of the review, we suggest a decision algorithm on the basis of the available evidence and provide practical recommendations for each of the anticoagulant options. In the third section, we discuss the limitations of the available evidence. On the basis of low-quality evidence, we find that patients with cancer and AF have a risk of stroke similar to that of the general population but a substantially higher risk of bleeding regardless of the anticoagulant agent used; this makes anticoagulation-related decisions complex and evidence from the general population not immediately applicable. In general, we suggest stopping anticoagulation in patients with high risk of bleeding and in those with a moderate bleeding risk without a high thromboembolic risk and recommend anticoagulation as in the general population for patients at a low risk for bleeding. However, regardless of initial therapy, we recommend reassessing whether anticoagulation should be given at each point in the clinical course of the disease. High-quality evidence to guide anticoagulation for AF in patients with cancer is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.